EPO Experimental Pharmacology & Oncology Berlin-Buch GmbH

  Spotlight on Our Breast Cancer and TNBC Models today! Discover how our orthotopic breast cancer models are transforming research by accurately replicating the metastatic process in vivo. These models mimic human disease progression, enabling precise tracking of human cells via PCR and detailed histological examinations. Our Breast Cancer Models are essential resources for understanding tumor biology and driving therapeutic innovation. Learn more about how they are advancing research and treatment development.

As the Tumor 12th Annual Models Boston Summit has started since 23th July, the EPO team has been connecting with many cooperating and also new partners at this meeting to discuss the current and broadened portfolio of EPO’s services. The EPO booth at the meeting is a good meeting point and the team of Jens Hoffmann (CEO) and Joe Herbert (EPO’s US representative) will be happy to meeting and welcoming anyone, who has interest in EPO’s drug discovery services using the great collection of our PDX, CDX and humanized mouse models.

As the Tumor 12th Annual Models Boston Summit has started since 23th July, the EPO team has been connecting with many cooperating and also new partners at this meeting to discuss the current and broadened portfolio of EPO’s services. The EPO booth at the meeting is a good meeting point and the team of Jens Hoffmann (CEO) and Joe Herbert (EPO’s US representative) will be happy to meeting and welcoming anyone, who has interest in EPO’s drug discovery services using the great collection of our PDX, CDX and humanized mouse models.

We are excited to be part of the upcoming Tumor Models Boston Summit in July. Stay tuned for updates as we approach the event!

New treatment option for therapy resistant lung cancer   „On June 13th, the European Patent Office approved our patent for the combination therapy of low-dose cabozantinib, afatinib, plerixafor and etoricoxib for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) without an oncogenic driver mutation under patent number 4196116.   This therapy regimen showed a high efficacy in treatment resistant human NSCLC tumors in the preclinical setting with a strong predictivity for the clinical setting. The research team is actively looking for collaboration partners setting up a clinical trial to evaluate this therapy regimen to provide hope for NSCLC patients without any more treatment options.   For further details please contact us via LinkedIn

We are at EACR in Rotterdam this week! Check out how we expanded our robust panel of pancreatic PDX models and how this can help to identify biomarkers for treatment response. Join us at tomorrow’s poster session to explore our project on long-term humanization of NOG mice. 🔔 Visit my colleagues at poster 345 and 398 to gain insights.   https://lnkd.in/dVVb_2GK

  A big thank you to all the speakers and guests at EPO’s Spring Meeting today! We were inspired by insightful presentations on new pre-clinical models and approaches, as well as recent clinical advancements. A perfect day for the EPO team at the beautiful Magnus-Haus under sunny skies and filled with networking, science and friendship. Thank you!

An exciting week lies ahead for EPO Berlin-Buch! This Thursday, we are thrilled to welcome numerous guests, friends, and colleagues to our traditional Spring Meeting in the heart of Berlin. We look forward to inspiring speakers, networking, and a delightful lunch in beautiful summery Berlin! 🔊 https://lnkd.in/dVVb_2GK

Check out EPO's latest poster presented by Simone Rhein today at CIMT 5pm - 7.30pm! 🔊 Poster#180: Assessment of therapeutic antibody efficacy without the interference of murine Fc receptors allows for investigation of human antibody-dependent cellular cytotoxicity mediated by NK cells in the FcResolv™ hIL-15 NOG mouse model

Hello Mainz! Day 2 of the CIMT meeting and if you get the chance, our colleague @Simone Rhein is presenting her poster today from 5pm – 7:30pm in the poster area. Explore our latest resulting from an excellent collaboration with Taconic Biosciences, highlighting how the murine Fc receptors can have positive or negative effects on the treatment efficacies of antibodies. Poster #180 in Poster Session May 16th, 5:00 pm - 7:30 pm. #CIMT2024 #EPO #Taconic